Head-to-head · WeighScore
FormidableMD vs Kin Meds
By GLP-1 ScorecardUpdated
Score comparison
FormidableMD has the higher recorded score — 73.2/100 to 69.1/100.
FormidableMD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. FormidableMD is a physician-led, cash-pay telehealth practice based in Florida offering GLP-1 weight-loss treatment — semaglutide and tirzepatide in both FDA-approved and compounded forms, plus oral options — alongside peptides, HRT/TRT, urgent care, labs, and nutrition coaching.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | FormidableMD | Kin Meds |
|---|---|---|
| WeighScore | 73.2/100 | 69.1/100 |
| Grade | C | C |
| Site position | #80 | #148 |
| Semaglutide | $169/mo (1 mg dose, compounded) | $149/mo (brand Wegovy) |
| Tirzepatide | $199/mo (10 mg dose, compounded) | $149/mo (brand Zepbound) |
| Coverage | 1 state | Coverage not published |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Yes | Yes |
Site position #80 · C
Strengths
- Transparent, published dose-by-dose pricing for semaglutide ($169-$269/mo) and tirzepatide ($199-$319/mo) with no membership or commitment
- Offers both FDA-approved and compounded GLP-1s (plus oral options) from 503A pharmacies, with a real provider at every visit
- Boutique physician-led model bundling labs, peptides, HRT/TRT and urgent care; FSA/HSA eligible
What to consider
- Florida-focused telehealth — availability outside FL is not advertised, so out-of-state access is uncertain
- Medication cost is on top of a $199 initial consultation and $99 follow-up visits (pay-per-visit, not an all-in monthly price)
- The 503A compounding pharmacy partner is not named on the site
Site position #148 · C
FDAWarning letter issued to Kin Meds in February 2026. See the FDA warning-letter database.
Strengths
- Publicly lists $199/mo compounded semaglutide and $249/mo compounded tirzepatide
- Brand-name options too — Wegovy injection and pill, Zepbound, Foundayo from $149/mo entry pricing
- LegitScript verified
- Clearly identifies itself as the intake platform and a licensed third-party pharmacy as the dispenser
- Broad longevity menu (Sermorelin, NAD+, Glutathione) plus TRT, hair, skin, and sexual health
What to consider
- Legal entity name and state of incorporation not publicly disclosed
- The third-party pharmacy partner isn't named, and Kin Meds isn't itself a licensed pharmacy
- Per-state availability not listed
- $149/mo brand pricing is the insured entry tier — cash-pay patients should expect higher real costs
- FDA issued Kin Meds a warning letter in February 2026; the letter is public in FDA's warning-letter database
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.